Tirzepatide's reach beyond weight, a once-weekly insulin combination, and a mood signal that needs calibrating

Randomized evidence dominated the week, and most of it came from inside trials already run — post hoc biomarker and risk-score analyses of SURMOUNT-1, a new population result from STEP 12. The pattern is consistent: GLP-1-class effects on metabolic and cardiovascular markers keep broadening. But only COMBINE 4 and STEP 12 report primary endpoints; the rest are secondary analyses that still need outcome data behind them.

• Tirzepatide moved a broad panel of cardiovascular risk markers in SURMOUNT-1 blood samples

  A post hoc analysis of the randomized SURMOUNT-1 obesity trial measured cardiovascular risk biomarkers in about 400 participants over 72 weeks. Tirzepatide was associated with large, dose-dependent reductions in inflammation markers — C-reactive protein fell as much as 55 percent, along with interleukin-6 — plus improvements in insulin resistance, leptin, and markers of blood-vessel and clotting health. A few markers did not move. The breadth suggests effects across multiple risk pathways, not just body weight, though post hoc biomarker findings are not counted heart events.

  Source ↗

• Once-weekly IcoSema outperformed daily insulin glargine on blood sugar in the COMBINE 4 randomized trial

  In this 40-week open-label phase 3b randomized trial of 485 adults with type 2 diabetes whose oral medications were no longer keeping blood sugar in range, a once-weekly injection combining basal insulin icodec with semaglutide lowered HbA1c more than daily insulin glargine — a 3.3-point drop versus 2.4. The combination group also lost a little weight while the glargine group gained nearly 4 kg, and had about half as many significant low-blood-sugar episodes. Stomach-related side effects were the most common complaint with the combination.

  Source ↗

• STEP 12: 12.1 percent average weight reduction with semaglutide in Chinese adults

  In a 44-week randomized, double-blind, placebo-controlled phase 3b trial of 242 Chinese adults with overweight or obesity, weekly semaglutide 2.4 mg produced an average 12.1 percent body-weight reduction versus 2.2 percent with placebo. About four in five participants on semaglutide lost at least 5 percent of their body weight. Stomach-related side effects were the most common complaint — consistent with the broader STEP program, now replicated in a new population.

  Source ↗

• Modeled 10-year heart-disease risk fell with three years of tirzepatide — calculated scores, not counted events

  In a follow-on analysis of the 3-year SURMOUNT-1 randomized trial, people with obesity and prediabetes on tirzepatide 15 mg saw their calculated 10-year heart-disease risk fall in a primary-prevention setting, while the placebo group's calculated risk rose. The authors themselves stress the limitation: these are modeled risk scores, not observed cardiovascular events, and dedicated outcome trials are still needed before the projection can be taken as fact.

  Source ↗

• Signal vs. noise: mood reports with GLP-1 drugs in a global side-effect database

  A reporting-pattern analysis of the WHO's spontaneous adverse-event database — not a trial or cohort, so it cannot establish causation or how common these symptoms are. Depressed mood and suicidal thoughts were reported somewhat more often with semaglutide, liraglutide, and tirzepatide than with other diabetes drugs, but absolute numbers were low and there was no increased signal for suicide attempts or deaths. Reporters more often had pre-existing depression or antidepressant use, which may explain much of the pattern. The authors suggest watching mood early in vulnerable patients.

  Source ↗

These are community reports and discussions — windows into what users notice and what research catches attention, not evidence. The most substantive thread this week concerns an observational dementia-risk finding; the rest are firsthand experience-sharing and practical explainers. Read them for texture and for the questions worth tracking, not for conclusions.

• r/science weighs a reported 26 percent lower predicted dementia risk with semaglutide

  A large discussion thread examines a study reporting that semaglutide use was associated with a 26 percent lower 5-year predicted dementia risk, part of growing research interest in possible neurocognitive effects of GLP-1 receptor agonists. Worth being precise about what this is: an observational, predictive finding — an association in modeled risk, not a demonstrated causal outcome.

  Source ↗

• GLP-1 users compare notes on what nobody warned them about

  An experience-sharing thread in r/Semaglutide asks users what surprised them most about GLP-1 use — unanticipated side effects, lifestyle adjustments, and unadvertised day-to-day realities. These are individual anecdotes, not clinical data, but threads like this often surface the practical texture that trial summaries leave out.

  Source ↗

• Peptides and drug testing: a community explainer for athletes and service members

  An r/PeptideLibrary overview of how peptide compounds interact with anti-doping and employment drug-testing regimes, aimed at athletes and service members weighing detection windows and prohibited-substance status. A practical-stakes topic that gets far less attention than efficacy discussions.

  Source ↗

• ARA-290 (cibinetide) gets a community explainer in a biohacking series

  Part of a biohacking explainer series covering ARA-290, an erythropoietin-derived peptide discussed in the community in small-fiber-nerve research contexts. It is not on our tracked-compound list — a reminder that community interest regularly runs ahead of the compounds with meaningful evidence bases.

  Source ↗